Yahoo Finance

• Revenue: Flat year-over-year, within the -3% to +1% corridor guidance for 2025.

• Core EPS: EUR2.49, on track to reach EUR4.50 to EUR5.00 at constant currencies.

• Free Cash Flow: Minus EUR1.5 billion, EUR1 billion improvement from last year.

• Crop Science Sales: Declined 3%, with regulatory impacts affecting higher margin sales.

• Pharmaceuticals Sales: Grew 4%, with Nubeqa and Kerendia increasing 80% year-over-year.

• Consumer Health Sales: Increased 2.5%, with 2% volume growth.

• EBITDA Before Special Items: EUR4.1 billion, 7% below prior-year quarter.

• Net Financial Debt: Increased by EUR1.7 billion to EUR34.3 billion since year-end 2024.

• Crop Science EBITDA Margin: 33.7%, 10% lower due to regulatory impacts and corn phasing.

• Pharmaceuticals EBITDA Margin: 29.5%, increased by 12% due to higher sales and efficiency gains.

• Consumer Health EBITDA Margin: 22.8%, slightly below prior year but within guidance range.

• Warning! GuruFocus has detected 3 Warning Sign with BAYRY.

Release Date: May 13, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Bayer AG (BAYRY) reported a strong performance in its Pharmaceuticals division with a 4% growth, driven by the exceptional momentum of Nubeqa and Kerendia, which grew 80% year-over-year.

• The company achieved a 12% increase in EBITDA before special items in the Pharmaceuticals division, indicating effective cost management and efficiency gains.

• Consumer Health division saw a 2.5% growth, with a 2% increase in volume, positioning the division well to meet its annual guidance.

• Bayer AG (BAYRY) is on track to meet its full-year guidance for 2025, with core EPS expected to be between EUR4.50 to EUR5.00 at constant currencies.

• The company has made significant progress in its strategic priorities, including the launch of Beyonttra in the EU and preparations for the launch of elinzanetant in the second half of the year.

Negative Points

• Bayer AG (BAYRY) reported a 3% decline in sales for its Crop Science division, primarily due to regulatory impacts affecting higher margin sales.

• The company's free cash flow was negative at EUR1.5 billion, attributed to the seasonality of the Crop business, although it showed improvement from the previous year.

• Xarelto sales declined by 31% due to continued generic pressure in Europe and Japan, impacting the Pharmaceuticals division's top and bottom line.

• The Consumer Health division experienced soft conditions in key markets, with a slight decline in margins compared to the previous year.

• Bayer AG (BAYRY) faces ongoing litigation challenges, including an adverse decision by the Superior Court of Pennsylvania, which may impact financial provisions and require further legal actions.